Detalhe da pesquisa
1.
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 402(10404): 775-785, 2023 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516125
2.
Atogepant for the Preventive Treatment of Migraine.
N Engl J Med
; 385(8): 695-706, 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407343
3.
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
Cephalalgia
; 43(1): 3331024221128250, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36620892
4.
Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
Headache
; 63(1): 79-88, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36651532
5.
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
Cephalalgia
; 42(1): 3-11, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521260
6.
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
Cephalalgia
; 39(14): 1753-1761, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31537107
7.
Italian Guidelines for the Management of Non-Functioning Benign and Locally Symptomatic Thyroid Nodules.
Endocr Metab Immune Disord Drug Targets
; 23(6): 876-885, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36722479
8.
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Netw Open
; 5(6): e2215499, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35675076
9.
Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.
Open Forum Infect Dis
; 6(1): ofy331, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30648126